CTNM — Contineum Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $452.99m
- $335.08m
- $50.00m
- 28
- 30
- 68
- 37
Annual balance sheet for Contineum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 69 | 47.2 | 125 |
| Prepaid Expenses | |||
| Total Current Assets | 69.8 | 48.4 | 128 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 0.642 | 2.12 | 1.4 |
| Other Long Term Assets | |||
| Total Assets | 70.5 | 50.6 | 130 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Current Liabilities | 3.67 | 7.55 | 5.48 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 8.93 | 11.4 | 5.7 |
| Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 61.6 | 39.3 | 125 |
| Total Liabilities & Shareholders' Equity | 70.5 | 50.6 | 130 |
| Total Common Shares Outstanding |